



Dermatology Reports

<https://www.pagepress.org/journals/index.php/dr/index>

eISSN 2036-7406



Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. **Dermatology Reports** is, therefore, E-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors.

Please cite this article as: Le TVT, Ngo AT, Ta QH, Vuong TBT. Serum interleukin 6 concentration in patients with pemphigus. Dermatol Rep 2023 [Epub Ahead of Print] doi: 10.4081/dr.2024.9868

 © the Author(s), 2024
Licensee PAGEPress, Italy

Submitted: 13/10/2023 – Accepted 12/11/2023

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Serum interleukin 6 concentration in patients with pemphigus

Thai Van Thanh Le,^{1,2} Anh Tuan Ngo,² Quoc Hung Ta,² The Bich Thanh Vuong¹

¹Department of Dermatology, University of Medicine and Pharmacy at Ho Chi Minh City;

²Department of Dermatology and Skin Aesthetics, Univesity Medical Center HCMC, Ho Chi Minh City, Vietnam

Correspondence: Anh Tuan Ngo, University of Medicine and Pharmacy, 217 Hong Bang, Ward 11, District 5, Ho Chi Minh City, Vietnam, 70000.

E-mail: anhtuanngo267@gmail.com

Key words: pemphigus vulgaris; pemphigus foliaceus; interleukin 6; pemphigus disease area index.

Contributions: the authors contributed equally.

Conflict of interest: the authors declare no potential conflict of interest.

Funding: none.

Ethical approval and consent to participate: this study was approved by the Biomedical Research Council of the University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam (approval number: 644/HDDD-DHYD, 23 November 2021).

Availability of data and materials: the data that support the findings of this study are available from the corresponding author upon reasonable request.

Informed consent: informed consent was received from all participants.

Abstract

Pemphigus is a rare autoimmune blistering disease that detrimentally affects the integumentary system and decreases patients' quality of life. Recent studies have shown that interleukin 6 (IL-6) is closely involved in the immunopathogenesis of pemphigus. Therefore, this study was performed to evaluate the role of IL-6 in the pathogenesis and severity of pemphigus disease. The case-series study was conducted in Ho Chi Minh City Hospital of Dermato-Venereology from January 2022 to August 2022, involving 26 patients with pemphigus vulgaris (PV), 4 patients with pemphigus foliaceus (PF), and 20 healthy volunteers. The serum IL-6 concentrations of patients with PV and PF were significantly higher than those of the healthy volunteers ($P < 0.001$). Serum IL-6 concentrations were significantly higher in patients with a positive than a negative Nikolsky sign ($P < 0.001$). A significant correlation was found between the serum IL-6 concentration and the pemphigus disease area index ($r = 0.8$, $P < 0.001$). Our results suggest that IL-6 may play an important role in the pathogenesis and severity of pemphigus. Therefore, new therapies targeting IL-6 may be a promising choice for treating pemphigus, especially in its severe forms.

Introduction

Pemphigus is a potentially life-threatening autoimmune blistering disease characterized by the autoantibody-induced breakage of adhesion molecules (desmogleins) between epidermal keratinocytes, resulting in acantholysis.(1) Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are two major variants of this disease, with different clinical presentations and pathogeneses.(2) The role of autoantibody-producing B lymphocytes in pemphigus has been determined, but the exact function of other immunocytes in the pathogenic pathway remains unclear.(3) Compared with PF, PV is more likely to recur and has a worse prognosis. Mouth ulcers in patients with PV are often resistant to treatment, and skin lesions in patients with PF can lead to erythroderma.(4) Since corticosteroids began to be used for treatment of pemphigus, the mortality rate has been reduced to 1.6%–12.0%. Nevertheless, the mortality rate remains two-fold higher in patients with pemphigus than in the general population.(5-7)

Despite the performance of numerous investigations worldwide, the exact mechanism of acantholysis in pemphigus has not been fully elucidated. Recent studies have shown that interleukin 6 (IL-6) is closely involved in the immunopathogenesis of pemphigus. The first study of IL-6 in patients with pemphigus was conducted in 1997, paving the way for other investigations of the IL-6 concentrations in serum and skin lesions. Most of these studies revealed increased IL-6

concentrations in both serum and skin lesions, suggesting that IL-6 plays a role in the immunological disturbances of patients with pemphigus.(8-13)

Given this background, the present study was performed to compare the serum IL-6 concentration in patients with PV and PF with that in healthy individuals. We also assessed the correlation between the serum IL-6 concentration and clinical severity using the pemphigus disease area index (PDAI).

Materials and Methods

Study subjects

This case series was conducted in Ho Chi Minh City Hospital of Dermato-Venereology from January 2022 to August 2022. Thirty patients with PV and PF were recruited. The diagnosis of pemphigus was based on clinical symptoms, histopathology, and direct immunofluorescence tests. All patients were ≥ 18 years of age. Patients with autoimmune diseases, acute or chronic infections, pregnancy, or any malignancies were excluded because of evidence that IL-6 is involved in such conditions.(14-18) All patients underwent a thorough physical examination and laboratory tests by dermatologists. The control group comprised 20 age- and sex-matched healthy volunteers.

Collection of biological samples

Venous blood specimens (3 mL) were collected from each patient and control subject into dipotassium ethylenediaminetetraacetic acid anticoagulant tubes and stored at -80°C until analysis. IL-6 quantification was then performed with an Elecsys IL-6 Kit (Roche, Basel, Switzerland) and enhanced chemiluminescence immunoassay according to the manufacturer's protocol.

Statistical analysis

All data were analyzed using Stata software version 14.2 (StataCorp, College Station, TX, USA). Because the laboratory data did not fit a Gaussian distribution according to the Shapiro–Wilk test, all results are expressed as median (50th percentile) and interquartile range (25th–75th percentile), and nonparametric tests were used to test for statistical significance (Mann–Whitney U test and Kruskal–Wallis test). For correlation studies, Spearman's rank correlation was used. In all calculations, $P < 0.05$ was regarded as statistically significant.

Results

Thirty patients (26 with PV, 4 with PF) and 20 healthy controls were enrolled in the study. Among all patients with pemphigus, the male:female ratio was 1:1 and the mean age was $52.5 \pm$

14.25 years (range, 32–81 years) (Table I). The mean PDAI score was 55.9 ± 33.77 (range, 12–154). Stratification of patients using the PDAI led to 17 patients in the extensive subgroup, 10 in the severe subgroup, and 3 in the moderate subgroup. The serum IL-6 concentrations were significantly different among these groups ($P = 0.005$) (Table II).

The serum IL-6 concentrations were significantly higher in the 30 patients with pemphigus than in the controls ($P < 0.001$) (Figure 1). The serum IL-6 concentrations were also significantly higher in patients with a positive than a negative direct Nikolsky test ($P < 0.001$). The difference in the serum IL-6 concentration between the PV and PF groups did not reach statistical significance. A significant correlation was found between the serum IL-6 concentration and the PDAI score ($r_s = 0.8$, $P < 0.001$) (Figure 2). There were no significant correlations between the serum IL-6 concentration and patient age or medications.

Discussion

Quantifying the serum levels of cytokines is a direct way to obtain valuable information about the role of cytokines in the pathogenesis of pemphigus. In this study, we compared the serum levels of IL-6, a very popular proinflammatory cytokine, between patients with pemphigus and controls.

Human IL-6 is comprised of 212 amino acids, including a 28-amino-acid signal peptide. The IL-6 gene is located on chromosome 7p21.(14) IL-6 is also known as a B-cell differentiation factor, but recent studies have shown that IL-6 is a multifunctional protein involved in immunological regulation, erythrocyte and platelet formation, and acute inflammation.(19) IL-6 can be produced by T cells, B cells, monocytes, fibroblasts, keratinocytes, and adipocytes.(15) Several studies have suggested that IL-6 is involved in autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and Crohn's disease.(14, 15, 20)

In the present study, the serum IL-6 concentrations were significantly higher in patients with pemphigus than in controls [18.95 (6.34–49.3) and 1.5 (1.5–2.695) pg/mL, respectively] ($P < 0.001$). In 1997, D'Auria *et al.*(9) conducted the first study to assess the serum IL-6 concentrations in 25 patients with PV and 20 controls. They reported that the serum IL-6 concentrations in patients with pemphigus [8.6 (0.3–45.0) pg/mL] were significantly higher than those in controls [1.6 (0.2–4.7) pg/mL] ($P < 0.001$). In 2012, Chriguier *et al.*(13) reported similar results, showing that the serum IL-6 concentrations of 12 patients with PF and 7 patients with PV were significantly higher than those of controls (934.5 ± 66.8 and 501.7 ± 87.9 pg/mL, respectively; $P < 0.005$). Masjedi *et al.*(8) and Keskin *et al.*(12) also found significant differences in the serum IL-6 levels between patients with pemphigus and controls ($P < 0.05$ and $P < 0.001$, respectively).

An important finding in our study is that the serum IL-6 concentrations were significantly higher in patients with a positive than a negative direct Nikolsky sign ($P < 0.001$). Narbutt *et al.*(11) also showed that the serum IL-6 concentration was higher in patients presenting with the active stage of PV than in patients who had achieved remission. However, the difference was not statistically significant. Our results support the role of IL-6 in the pathogenesis of pemphigus, especially in the active stage of the disease.

Consistent with these findings, we also found a positive and significant correlation between the serum IL-6 concentration and the PDAI score ($r_s = 0.8$, $P < 0.001$). D'Auria *et al.*(9) also showed a positive correlation between the serum IL-6 concentration and the number of skin lesions ($r = 0.9$, $P < 0.001$). In 2020, Metwally *et al.*(21) reported a similar correlation between the serum IL-6 concentration and the pemphigus area and activity score ($P = 0.03$).

In the present study, we found no significant differences in the serum IL-6 concentrations between treatment-naïve patients, patients treated with corticosteroids at ≤ 0.5 mg/kg/day, patients treated with corticosteroids at > 0.5 mg/kg/day, and patients treated with corticosteroids in combination with immunosuppressants ($P > 0.05$). This result is in line with that of Mortazavi *et al.*,(22) who found that the serum IL-6 concentrations in patients with PV after 6 months of treatment with corticosteroids were not significantly different from those in the patients at onset. Chrighuer *et al.*(13) also found that IL-6 synthesis in patients with PV was not inhibited even with high doses of dexamethasone.

Limitations of this study: The sample size was small due to the rarity of pemphigus, and no sex- or age-matching protocols were used when recruiting participants in the control group. Multicenter studies with larger sample size are needed to confirm our results and obtain more data on pemphigus patients.

Conclusions

In summary, this study provides further support for the role of IL-6 in the pathogenesis of PV and PF. In addition, a strong correlation between serum IL-6 and disease severity was found in our study, similar to other research. It was recently shown that anti-IL-6 therapies could be an effective option for treating autoinflammatory diseases such as rheumatoid arthritis and Crohn's disease.(23) Therefore, new therapies targeting IL-6 may be a promising choice for treating pemphigus, especially in its severe forms.

References

1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. *Autoimmunity*. 2012;45(1):7-35.
2. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. *Lancet* (London, England). 2019;394(10201):882-94.
3. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. *The Journal of investigative dermatology*. 2000;114(1):88-94.
4. Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, Kurosawa M, et al. Japanese guidelines for the management of pemphigus. *The Journal of dermatology*. 2014;41(6):471-86.
5. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. *BMJ* (Clinical research ed). 2008;337(7662):a180.
6. Huang YH, Kuo CF, Chen YH, Yang YW. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. *The Journal of investigative dermatology*. 2012;132(1):92-7.
7. Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the U.S.A. *The British journal of dermatology*. 2016;174(6):1290-8.
8. Masjedi M, Esmaeil N, Saffaei A, Abtahi-Naeini B, Pourazizi M, Haghjooy Javanmard S, et al. Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunopathogenesis and Hopes for Non-Steroidal Treatment. *Iranian journal of pharmaceutical research : IJPR*. 2017;16(3):1223-9.
9. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. *European cytokine network*. 1997;8(4):383-7.
10. López-Robles E, Avalos-Díaz E, Vega-Memije E, Hojyo-Tomoka T, Villalobos R, Fraire S, et al. TNFalpha and IL-6 are mediators in the blistering process of pemphigus. *International journal of dermatology*. 2001;40(3):185-8.
11. Narbutt J, Lukamowicz J, Bogaczewicz J, Sysa-Jedrzejowska A, Torzecka JD, Lesiak A. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. *Mediators of inflammation*. 2008;2008:875394.

12. Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. *Cytokine*. 2008;41(3):315-21.
13. Chriguer RS, Roselino AM, de Castro M. Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus. *Journal of clinical immunology*. 2012;32(4):786-93.
14. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harbor perspectives in biology*. 2014;6(10):a016295.
15. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. *Clinical science (London, England : 1979)*. 2012;122(4):143-59.
16. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. *Nature reviews Rheumatology*. 2017;13(7):399-409.
17. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2016;37(9):11553-72.
18. Fu Y, Tang L, Hu M, Xiang Z, Hu Y. Changes of serum interleukin-6 in healthy pregnant women and establishment of relevant reference intervals. *Clinica chimica acta; international journal of clinical chemistry*. 2020;502:116-9.
19. Kishimoto T. Factors affecting B-cell growth and differentiation. *Annual review of immunology*. 1985;3:133-57.
20. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. *Cytokine & growth factor reviews*. 2002;13(4-5):357-68.
21. Metwally D, Fawzy M, ElKalioby M, Hegazy R, Hay RA, Abd-Elreheem H, et al. Assessment of the Quality of Life, Prevalence of Depression, and the Level of Interleukin 6 in Patients with Pemphigus Vulgaris. *Acta dermatovenerologica Croatica : ADC*. 2020;28(2):57-62.
22. Mortazavi H, Esmaili N, Khezri S, Khamesipour A, Vasheghani Farahani I, Daneshpazhooh M, et al. The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. *Iranian journal of allergy, asthma, and immunology*. 2014;13(3):174-83.
23. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. *Current opinion in pharmacology*. 2004;4(4):386-91.

Table 1. Distribution of age and sex in patients and controls.

Characteristics		Patients	Controls	P
Age, years		52.5±14.25	52.6±14.35	0.95 ^a
Age group	<40 years	8 (26.67)	5 (25.0)	0.95 ^a
	40-59 years	12 (40.0)	8 (40.0)	
	≥60 years	10 (33.33)	7 (35.0)	
Sex	Male	15 (50.0)	10 (50.0)	1 ^a
	Female	15 (50.0)	10 (50.0)	
Total		30	20	

Data are presented as mean ± standard deviation or n (%). ^aMann-Whitney test.

Table 2. Serum IL-6 concentrations in severity subgroups according to PDAI.

Severity	Frequency, n	Serum IL-6 concentration, pg/mL	P
Moderate	3	6.17 (4.85–7.25)	0.005 ^a
Severe	10	8 (4.54–33.8)	
Extended	17	46.15 (16.75–64.45)	

IL-6, interleukin 6; IL-6 concentration is presented as median (interquartile range). ^aKruskal–Wallis test.




Figure 1. Comparison of serum IL-6 concentrations. The box-plot shows the median and percentiles (25th, 75th) of the serum IL-6 concentrations between patients with pemphigus and controls. IL-6, interleukin 6.




Figure 2. Correlation between serum IL-6 concentration and PDAI score. IL-6, interleukin 6; PDAI, pemphigus disease area index.